Our top pick for
MEDNAX, Inc is a medical care facilities business based in the US. MEDNAX shares (MD) are listed on the NYSE and all prices are listed in US Dollars. MEDNAX employs 9,480 staff and has a trailing 12-month revenue of around USD$3.5 billion.
Since the stock market crash in March caused by coronavirus, MEDNAX's share price has had significant negative movement.
Its last market close was USD$19.74, which is 1.25% down on its pre-crash value of USD$19.99 and 167.84% up on the lowest point reached during the March crash when the shares fell as low as USD$7.37.
If you had bought USD$1,000 worth of MEDNAX shares at the start of February 2020, those shares would have been worth USD$411.38 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$841.52.
|Latest market close||USD$19.74|
|52-week range||USD$7.37 - USD$28.66|
|50-day moving average||USD$15.7833|
|200-day moving average||USD$17.1697|
|Wall St. target price||USD$19|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.441|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-16)||19.74|
|1 month (2020-10-26)||42.01%|
|3 months (2020-08-24)||4.94%|
|6 months (2020-05-22)||30.13%|
|1 year (2019-11-22)||-25.65%|
|2 years (2018-11-23)||-49.99%|
|3 years (2017-11-24)||-59.80%|
|5 years (2015-11-24)||-73.50%|
Valuing MEDNAX stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MEDNAX's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
MEDNAX's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, MEDNAX shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
MEDNAX's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.88. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MEDNAX's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
MEDNAX's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$452.3 million.
The EBITDA is a measure of a MEDNAX's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$3.5 billion|
|Operating margin TTM||10.59%|
|Gross profit TTM||USD$892 million|
|Return on assets TTM||6.02%|
|Return on equity TTM||-104.75%|
|Market capitalisation||USD$1.6 billion|
TTM: trailing 12 months
There are currently 9.4 million MEDNAX shares held short by investors – that's known as MEDNAX's "short interest". This figure is 24.5% up from 7.6 million last month.
There are a few different ways that this level of interest in shorting MEDNAX shares can be evaluated.
MEDNAX's "short interest ratio" (SIR) is the quantity of MEDNAX shares currently shorted divided by the average quantity of MEDNAX shares traded daily (recently around 903879.71291866). MEDNAX's SIR currently stands at 10.45. In other words for every 100,000 MEDNAX shares traded daily on the market, roughly 10450 shares are currently held short.
However MEDNAX's short interest can also be evaluated against the total number of MEDNAX shares, or, against the total number of tradable MEDNAX shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MEDNAX's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 MEDNAX shares in existence, roughly 110 shares are currently held short) or 0.1302% of the tradable shares (for every 100,000 tradable MEDNAX shares, roughly 130 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against MEDNAX.
Find out more about how you can short MEDNAX stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like MEDNAX.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 19.73
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and MEDNAX's overall score of 19.73 (as at 01/01/2019) is pretty good – landing it in it in the 22nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like MEDNAX is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.84/100
MEDNAX's environmental score of 1.84 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that MEDNAX is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 8.57/100
MEDNAX's social score of 8.57 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that MEDNAX is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 5.5/100
MEDNAX's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that MEDNAX is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. MEDNAX scored a 1 out of 5 for controversy – the highest score possible, reflecting that MEDNAX has managed to keep its nose clean.
|Total ESG score||19.73|
|Total ESG percentile||21.62|
|Environmental score percentile||1|
|Social score percentile||1|
|Governance score percentile||1|
|Level of controversy||1|
We're not expecting MEDNAX to pay a dividend over the next 12 months.
MEDNAX's shares were split on a 2:1 basis on 20 December 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your MEDNAX shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for MEDNAX shares which in turn could have impacted MEDNAX's share price.
Over the last 12 months, MEDNAX's shares have ranged in value from as little as $7.37 up to $28.66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while MEDNAX's is 1.6539. This would suggest that MEDNAX's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and their unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patients with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, pediatric ophthalmology, other newborn pediatric care, and newborn hearing screening program, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. Additionally, it offers consulting services to healthcare facilities and physicians. As of March 12, 2020, the company operated a network of approximately 4,325 physicians. MEDNAX, Inc. was founded in 1979 and is based in Sunrise, Florida.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.